Brief: VBI Vaccines Announces FDA Approval Of PreHevbrio For Prevention Of Hepatitis B
01/12/2021 12:39
Dec 1 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES ANNOUNCES FDA APPROVAL OF PREHEVBRIO™ FOR THE
PREVENTION OF HEPATITIS B IN ADULTS
* VBI VACCINES INC - EXPECTS TO MAKE PREHEVBRIO AVAILABLE IN
U.S.
IN Q1 OF 2022
Source text for Eikon: ID:nBw3sbj5Qa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55